MolDX: Blood Product Molecular Antigen Typing

Molecular blood product antigen typing is covered for pre-transfusion evaluation when patients are expected to require long-term frequent transfusions, when serologic testing is confounded by autoantibodies or other reactivity, when typing sera are unavailable, or to resolve serologic typing discrepancies. LDTs may be covered if a technical assessment shows equivalent or superior validity and clinical utility; single-gene tests are generally not considered reasonable and necessary except rarely with documented utility, and testing is not expected for routine surgical patients or those with serologically identifiable alloantibodies who will not need frequent transfusions.

"Molecular phenotyping of blood product antigens is covered as part of pre-transfusion evaluation for patients who are expected to require long-term, frequent transfusions to prevent alloantibody de..."